120 related articles for article (PubMed ID: 23053402)
1. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
Ogawa T; Niho S; Nagai S; Kojima T; Nishimura Y; Ohe Y; Kondo N; Yamaguchi T; Endo K; Izumi K; Minami H
Int J Clin Oncol; 2013 Dec; 18(6):977-82. PubMed ID: 23053402
[TBL] [Abstract][Full Text] [Related]
2. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
3. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
4. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H
Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
[TBL] [Abstract][Full Text] [Related]
6. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
7. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
8. [Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
Takagi M; Sagara A; Ishizawa A; Ito A; Miyazaki M; Senzaki K; Nagai T; Yamada K
Yakugaku Zasshi; 2019; 139(10):1327-1332. PubMed ID: 31582618
[TBL] [Abstract][Full Text] [Related]
9. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
10. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with
Khurana R; Deswal S; Prakash C; Singh DK
J Clin Diagn Res; 2016 Dec; 10(12):XC05-XC07. PubMed ID: 28208988
[TBL] [Abstract][Full Text] [Related]
12. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
14. Renal tolerance of cisplatin in patients more than 80 years old.
Thyss A; Saudes L; Otto J; Creisson A; Gaspard MH; Dassonville O; Schneider M
J Clin Oncol; 1994 Oct; 12(10):2121-5. PubMed ID: 7931482
[TBL] [Abstract][Full Text] [Related]
15. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity.
Koçak G; Bilik G; Yeşilova A; Oyman F; Can M; Cihan Ş
Medicine (Baltimore); 2022 Jul; 101(26):e29814. PubMed ID: 35777022
[TBL] [Abstract][Full Text] [Related]
17. eGFR is a reliable preoperative renal function parameter in patients with gastric cancer.
Kosuge T; Sawada T; Iwasaki Y; Kita J; Shimoda M; Tagaya N; Kubota K
World J Gastroenterol; 2010 May; 16(19):2417-20. PubMed ID: 20480529
[TBL] [Abstract][Full Text] [Related]
18. High-dose cisplatin in patients with advanced malignancies.
Blumenreich MS; Woodcock TM; Jones M; Richman SP; Gentile PS; Kubota TT; Allegra JC
Cancer; 1985 Mar; 55(5):1118-22. PubMed ID: 4038468
[TBL] [Abstract][Full Text] [Related]
19. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
20. Derivation of a new equation for estimating creatinine clearance by using fat-free mass and serum creatinine concentration in Korean patients with type 2 diabetes mellitus.
Lee EK; Cho YM; Kim JT; Koo BK; Cho HY; Ku YH; Park KS; Jang HC; Kim SY; Lee HK
Diabetes Res Clin Pract; 2009 Jan; 83(1):44-9. PubMed ID: 19027979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
